Recombinant Human GalNAc-T16 (Polypeptide N-acetylgalactosaminyltransferase 16), soluble fragment
Polypeptide N-acetylgalactosaminyltransferase 16 (GalNAc-T16) catalyzes the transfer of N-acetylgalactosamine (GalNAc) from UDP-GalNAc to the hydroxyl group of serine and threonine residues (1). Twenty GalNAc-T genes have been identified in humans and most have been shown to represent active GalNAc-Ts. All isoforms are type II transmembrane proteins, with different but partly overlapping substrate preferences (2). The GalNAc-Ts control the initiation of mucin-type O-linked glycosylation and determine the location and density of O-glycans in a protein (2). Addition of GalNAc to an unglycosylated Ser/Thr residue creates the Tn antigen GalNAcα1-S/T, and subsequent addition of sialic acid by ST6GalNAc-I forms the cancer associated STn antigen (3).
- Bennet, E.P. Submitted (AUG-2002) to the EMBL/GenBank/DDBJ databases.
- Tian, E. & Ten Hagen, K.G. (2009) Glycocon. J. 26, 325.
- Sewell, R. et al. (2006) J. Biol. Chem. 281, 3586.
Catalog #: SBH-003- GalNAc-T16
Source : Insect Cells, Accession # Q68VJ8
Formulation: Sterile filtered solution in 25mM Tris pH7.5 and 150mM NaCl, at a stock concentration of 100 ug/mL.
Stability: Stable for 4 weeks at 4C. Stable for 6 months at -80C. Avoid repeated freeze-thaw cycles.
Purity: Greater than 90% by SDS-PAGE.
Biological Activity: In Progess
UniProt Link: GalNAc-T16 Human
Usage: For research only. Not for use in diagnostic or therapeutic procedures.
Country of Origin: USA